Cargando…

Panobinostat for the treatment of multiple myeloma: the evidence to date

Multiple myeloma is a malignancy involving plasma cell proliferation within the bone marrow. Survival of patients diagnosed with myeloma has significantly improved in the last decade, following the approval of novel agents. Despite great strides achieved in the management of multiple myeloma, it is...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bailey, Hanna, Stenehjem, David D, Sharma, Sunil
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2015
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4603728/ https://www.ncbi.nlm.nih.gov/pubmed/26504410 http://dx.doi.org/10.2147/JBM.S69140

Ejemplares similares

Efficacy of Panobinostat for the Treatment of Multiple Myeloma
por: Eleutherakis-Papaiakovou, Evangelos, et al.
Publicado: (2020)

Panobinostat and Multiple Myeloma in 2018
por: Yee, Andrew J., et al.
Publicado: (2018)

The Combination of Panobinostat and Melphalan for the Treatment of Patients with Multiple Myeloma
por: Gkotzamanidou, Maria, et al.
Publicado: (2022)

Spotlight on elotuzumab in the treatment of multiple myeloma: the evidence to date
por: Weisel, Katja
Publicado: (2016)

EMA Review of Panobinostat (Farydak) for the Treatment of Adult Patients with Relapsed and/or Refractory Multiple Myeloma
por: Tzogani, Kyriaki, et al.
Publicado: (2018)

EMA Review of Panobinostat (Farydak) for the Treatment of Adult Patients with Relapsed and/or Refractory Multiple Myeloma
por: Tzogani, Kyriaki, et al.
Publicado: (2017)

Evaluating the Therapeutic Potential of Idecabtagene Vicleucel in the Treatment of Multiple Myeloma: Evidence to Date
por: Mann, Hashim, et al.
Publicado: (2022)

Clinical developments in the treatment of relapsed or relapsed and refractory multiple myeloma: impact of panobinostat, the first-in-class histone deacetylase inhibitor
por: Redic, Kimberly A, et al.
Publicado: (2016)

The Role of Panobinostat Plus Bortezomib and Dexamethasone in Treating Relapsed or Relapsed and Refractory Multiple Myeloma: A European Perspective
por: San-Miguel, Jesus F., et al.
Publicado: (2016)

PDI inhibitor LTI6426 enhances panobinostat efficacy in preclinical models of multiple myeloma
por: Robinson, Reeder M., et al.
Publicado: (2022)

Pooled analysis of the reports of carfilzomib, panobinostat, and elotuzumab combinations in patients with refractory/relapsed multiple myeloma
por: Liu, Liping, et al.
Publicado: (2016)

Expression of histone deacetylase (HDAC) family members in bortezomib-refractory multiple myeloma and modulation by panobinostat
por: Cheng, Tiewei, et al.
Publicado: (2021)

Combining carfilzomib and panobinostat to treat relapsed/refractory multiple myeloma: results of a Multiple Myeloma Research Consortium Phase I Study
por: Kaufman, Jonathan L., et al.
Publicado: (2019)

Panobinostat PK/PD profile in combination with bortezomib and dexamethasone in patients with relapsed and relapsed/refractory multiple myeloma
por: Mu, Song, et al.
Publicado: (2015)

Efficacy and Safety of Panobinostat in Relapsed or/and Refractory Multiple Myeloma: Meta Analyses of Clinical Trials and Systematic Review
por: Liu, Jing-di, et al.
Publicado: (2016)

PD-L1 upregulation in myeloma cells by panobinostat in combination with interferon-γ
por: Iwasa, Masami, et al.
Publicado: (2019)

Synergistic Activity of Carfilzomib and Panobinostat in Multiple Myeloma Cells via Modulation of ROS Generation and ERK1/2
por: Gao, Lu, et al.
Publicado: (2015)

Phase 1 open-label study of panobinostat, lenalidomide, bortezomib + dexamethasone in relapsed and relapsed/refractory multiple myeloma
por: Laubach, Jacob P., et al.
Publicado: (2021)

Profile of panobinostat and its potential for treatment in solid tumors: an update
por: Anne, Madhurima, et al.
Publicado: (2013)

Panobinostat in combination with bortezomib and dexamethasone in multiply relapsed and refractory myeloma; UK routine care cohort
por: Maouche, Nadjoua, et al.
Publicado: (2022)

Phase II trial of single‐agent panobinostat consolidation improves responses after sub‐optimal transplant outcomes in multiple myeloma
por: Mithraprabhu, Sridurga, et al.
Publicado: (2020)

Panobinostat synergizes with zoledronic acid in prostate cancer and multiple myeloma models by increasing ROS and modulating mevalonate and p38-MAPK pathways
por: Bruzzese, F, et al.
Publicado: (2013)

Brolucizumab: evidence to date in the treatment of neovascular age-related macular degeneration
por: Yannuzzi, Nicolas A, et al.
Publicado: (2019)

Estimating the Economic Impact of Adding Panobinostat to a U.S. Formulary for Relapsed and/or Refractory Multiple Myeloma: A Budget Impact and Cost-Benefit Model
por: Bloudek, Lisa, et al.
Publicado: (2016)

EZH2 inhibitors sensitize myeloma cell lines to panobinostat resulting in unique combinatorial transcriptomic changes
por: Harding, Taylor, et al.
Publicado: (2018)

Fremanezumab in the treatment of migraines: evidence to date
por: Robblee, Jennifer, et al.
Publicado: (2019)

Guselkumab for the treatment of psoriasis – evidence to date
por: Nogueira, Miguel, et al.
Publicado: (2019)

Panobinostat as Pan-deacetylase Inhibitor for the Treatment of Pancreatic Cancer: Recent Progress and Future Prospects
por: Singh, Avineesh, et al.
Publicado: (2016)

Effects of Histone Deacetylase Inhibitor Panobinostat (LBH589) on Bone Marrow Mononuclear Cells of Relapsed or Refractory Multiple Myeloma Patients and Its Mechanisms
por: Ma, Yanping, et al.
Publicado: (2017)

Bowman’s layer transplantation: evidence to date
por: Sharma, Bhavana, et al.
Publicado: (2018)

Spotlight on siponimod and its potential in the treatment of secondary progressive multiple sclerosis: the evidence to date
por: Gajofatto, Alberto
Publicado: (2017)

Evidence to date: talazoparib in the treatment of breast cancer
por: Exman, Pedro, et al.
Publicado: (2019)

Profile of Glasdegib for the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML): Evidence to Date
por: Iyer, Sunil Girish, et al.
Publicado: (2022)

Spotlight on brodalumab in the treatment of plaque psoriasis: the evidence to date
por: Galluzzo, M, et al.
Publicado: (2019)

Dabrafenib–Panobinostat Salt: Improving the Dissolution Rate and Inhibition of BRAF Melanoma Cells
por: Rai, Sunil K., et al.
Publicado: (2023)

Combination Antiangiogenic and Immunotherapy for Advanced Hepatocellular Carcinoma: Evidence to Date
por: Raybould, Alison L, et al.
Publicado: (2020)

Synergistic targeting of Sp1, a critical transcription factor for myeloma cell growth and survival, by panobinostat and proteasome inhibitors
por: Bat-Erdene, Ariunzaya, et al.
Publicado: (2016)

Elotuzumab for the treatment of multiple myeloma
por: Wang, Yucai, et al.
Publicado: (2016)

A phase I/II study of the combination of panobinostat and carfilzomib in patients with relapsed or relapsed/refractory multiple myeloma: Final analysis of second dose‐expansion cohort
por: Berdeja, Jesus G., et al.
Publicado: (2021)

Current Perspectives: Evidence to Date on BTK Inhibitors in the Management of Multiple Sclerosis
por: Carnero Contentti, Edgar, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_o9g27h6lb4dgj15hp69tqod79r